Načítá se...
Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells
Ontak(®), a conjugate between IL-2 and a diphtheria toxin fragment, was recently investigated in cancer clinical trials aiming to kill CD25(+) regulatory T cells (T(regs)). We found that the activity of Ontak(®) was more complex on T(regs) and conventional T cells (T(convs)) than anticipated, includ...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Landes Bioscience
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4091105/ https://ncbi.nlm.nih.gov/pubmed/25050193 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.28223 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|